Wyndham Wilson

Wyndham Wilson, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Lymphoid Malignancies Branch


Although significant strides have been made in the treatment of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL), major clinical advances have plateaued over despite the development of new chemotherapy regimens and strategies. In an attempt to improve the therapy for lymphomas, we have focused our studies on several promising areas of research:

  1. Strategies to reverse drug resistance; 
  2. Schedule dependence of cytotoxic agents and dose intensity;
  3. Development of novel agents, with a focus on T cell toxins;
  4. Identification of clinical mechanisms of drug resistance.

Areas of Expertise

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them. 


Selected Recent Publications

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma

Roschewski M, Dunleavy K, Abramson JS, Powell BL, Link BK, Patel P, Bierman PJ, Jagadeesh D, Mitsuyasu RT, Peace D, Watson PR, Hanna WT, Melani C, Lucas AN, Steinberg SM, Pittaluga S, Jaffe ES, Friedberg JW, Kahl BS, Little RF, Bartlett NL, Fanale MA, Noy A, Wilson WH.
J Clin Oncol. [Epub ahead of print], 2020. [ Journal Article ]

Randomized Phase II Study of First-Line Cladribine With Concurrent or Delayed Rituximab in Patients With Hairy Cell Leukemia

Chihara D, Arons E, Stetler-Stevenson M, Yuan CM, Wang HW, Zhou H, Raffeld M, Xi L, Steinberg SM, Feurtado J, James L, Wilson W, Braylan RC, Calvo KR, Maric I, Dulau-Florea A, Kreitman RJ.
J Clin Oncol. 38(14): 1527-38, 2020. [ Journal Article ]

Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder

Melani C, Jaffe ES, Wilson WH.
Blood. 135(16): 1344-52, 2020. [ Journal Article ]

Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study

Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH.
Lancet Haematol. 5(12): e609-e617, 2018. [ Journal Article ]

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I.
Blood. 131(21): 2331-34, 2018. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


Clinical Collaborator
Jaime Piercey Gastwirt, M.D.
Research Nurse (Contr.)
Anna Marie Juanitez, R.N.
Clinical Research Nurse
Andrea Lucas, R.N.
Nurse Practitioner
Candis Morrison, NP